Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)
NCT07290257
·
clinicaltrials.gov ↗
PHASE4
Phase
RECRUITING
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Alagille Syndrome
Interventions
DRUG:
Livmarli Oral Product
Sponsor
Mirum Pharmaceuticals, Inc.